We surmise that the potential role(s) of the iNOS inhibitor and that of the TMPRSS2 inhibitor in the renal microvascular remodeling, could prove to be novel as also demonstrated by other investigators that during glomerulosclerosis in COVID-19 and its mitigation by TMPRSS2 inhibitor(s) is indeed therapeutically novel concept18. Here, NOS2 is linked to glomerulosclerosis.